[Hyperlipoproteinemias and proteinase inhibitor balance in patients with proliferative diabetic retinopathy with solid exudates in retina].
Studies of lipid metabolism and proteinase inhibitor balance in the blood of patients with proliferative diabetic retinopathy (PDR) revealed hyperlipoproteinemias (HLP) in 61%. Type IIa HLP predominated (32%), type IV HLP were diagnosed in 23%, and type IIb in 7% of cases. Solid exudations in the retina were 7 times more frequent in patients with type IV HLP and 5 times more frequent in those with type IIb HLP than in patients without HLP. The most expressed shifts of proteinase inhibitor balance towards increase of trypsin-like activity, which was not compensated for by the antitryptic potential, were observed in the same two groups. The data indicate that PDR patients with types IIb and IV HLP with increased blood proteolytic activity not compensated for by inhibitors are at a high risk of developing solid exudations in the retina. Therefore individual drug correction of lipid metabolism and proteinase inhibitor balance is recommended for maintaining visual function in diabetics. The treatment should be based on the results of clinical and biochemical studies.
Chesnokova
N B
NB
Kuznetsova
T P
TP
Davydova
G A
GA
Grigor'ev
A V
AV
D000328:Adult; D000368:Aged; D003930:Diabetic Retinopathy / Q000097:blood* / Q000150:complications; D010450:Endopeptidases / Q000097:blood; D005122:Exudates and Transudates; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood* / Q000150:complications; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011480:Protease Inhibitors / Q000493:pharmacokinetics*; D012160:Retina / Q000473:pathology*
D008074:Lipoproteins; D011480:Protease Inhibitors; D010450:Endopeptidases